Literature DB >> 1350805

Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.

C A Smith1, A C Gough, P N Leigh, B A Summers, A E Harding, D M Maraganore, S G Sturman, A H Schapira, A C Williams, D M Maranganore.   

Abstract

The pathogenesis of Parkinson's disease may be influenced by genetic and environmental factors. Cytochrome P450 mono-oxygenases help to protect against toxic environmental compounds and individual variations in cytochrome P450 expression might, therefore, influence susceptibility to environmentally linked diseases. The frequency of mutant CYP2D6 alleles was studied in 229 patients with Parkinson's disease and 720 controls. Individuals with a metabolic defect in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene with the poor metaboliser phenotype had a 2.54-fold (95% Cl 1.51-4.28) increased risk of Parkinson's disease. Determination of CYP2D6 phenotype and genotype may help to identify those at greatest risk of Parkinson's disease and may also help to identify the environmental or metabolic agents involved in the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350805     DOI: 10.1016/0140-6736(92)91196-f

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  77 in total

1.  Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis.

Authors:  N A Wong; F Rae; K J Simpson; G D Murray; D J Harrison
Journal:  Mol Pathol       Date:  2000-04

2.  CYP2D6 deficiency, a factor in ecstasy related deaths?

Authors:  T C Gilhooly; A K Daly
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 3.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

Review 4.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

5.  The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease.

Authors:  T Gasser; B Müller-Myhsok; A Supala; E Zimmer; G Wieditz; Z K Wszolek; P Vieregge; V Bonifati; W H Oertel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-11       Impact factor: 10.154

6.  A novel cytochrome P-450IID6 (CYPIID6) mutant gene associated with multiple system atrophy.

Authors:  K Iwahashi; R Miyatake; Y Tsuneoka; Y Matsuo; Y Ichikawa; K Hosokawa; K Sato; T Hayabara
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

7.  Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.

Authors:  Anna-Britta Lind; Margareta Reis; Finn Bengtsson; Michele Jonzier-Perey; Kerry Powell Golay; Johan Ahlner; Pierre Baumann; Marja-Liisa Dahl
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Cytochrome P4502D6 genotype does not determine response to clozapine.

Authors:  M J Arranz; E Dawson; S Shaikh; P Sham; T Sharma; K Aitchison; M A Crocq; M Gill; R Kerwin; D A Collier
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

9.  Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.

Authors:  H Madsen; K K Nielsen; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

10.  Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease.

Authors:  Prachi Bajpai; Michelle C Sangar; Shilpee Singh; Weigang Tang; Seema Bansal; Goutam Chowdhury; Qian Cheng; Ji-Kang Fang; Martha V Martin; F Peter Guengerich; Narayan G Avadhani
Journal:  J Biol Chem       Date:  2012-12-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.